High glucose‐induced complement component 3 up‐regulation via <scp>RAGE</scp>‐p38<scp>MAPK</scp>‐<scp>NF</scp>‐κB signalling in astrocytes: In vivo and in vitro studies

Yuxing Zhao, Cheng Luo, Jinliang Chen, Yue Sun, Die Pu, Ankang Lv, Shiyu Zhu, Jing Wu, Meili Wang, Jing Zhou, Zhiyin Liao, Kexiang Zhao, Qian XiaoJournal of Cellular and Molecular Medicine 2018 · DOI

TL;DR

This study reveals a novel molecular pathway by which high glucose levels in diabetes lead to increased complement component 3 (C3) production in astrocytes. This upregulation, mediated by the RAGE-p38MAPK-NF-κB signaling cascade, is linked to synaptic damage, offering a potential therapeutic target for diabetic cognitive decline.

What Problem Does This Paper Address?

Diabetes mellitus is a well-established risk factor for cognitive decline, often accompanied by neurodegenerative changes and heightened innate immune system activity in the brain. While the complement system, particularly complement component 3 (C3), is known to play a role in neurodegenerative conditions, its specific involvement and regulation in diabetic neuropathology remained unclear. Furthermore, the receptor for advanced glycation end products (RAGE), known to mediate inflammatory responses, has been implicated in neurodegeneration, but its precise role in C3 regulation in the context of diabetes was not understood. This paper aims to bridge this knowledge gap by investigating how high glucose levels in diabetes affect C3 production in astrocytes and to elucidate the underlying RAGE-dependent signaling mechanisms.

Methods

The researchers employed a multi-pronged approach combining in vivo and in vitro studies.

  • Animal Model: Streptozotocin (STZ)-induced diabetic mice were used to mimic diabetic conditions. These mice were treated with a RAGE-specific inhibitor (FPS-ZM1) to assess the role of RAGE.
  • Cell Culture: Primary astrocytes were isolated from mouse pups and cultured. These astrocytes were then exposed to high glucose (HG) conditions, with and without inhibitors for RAGE, p38MAPK, and NF-κB.
  • Molecular Biology Techniques:
    • Western Blotting: Used to quantify protein levels of C3, RAGE, p38MAPK (phosphorylated and total), and NF-κB (phosphorylated and total) in both brain tissue and cell extracts.
  • Quantitative RT-PCR (qRT-PCR): Employed to measure C3 mRNA expression.
  • ELISA: Utilized to assess the secretion of C3 into the cell culture medium.
  • Immunofluorescence Staining: Performed to visualize the co-localization of C3 with GFAP (a marker for astrocytes) and synaptophysin (a presynaptic protein marker) in brain tissue and cultured astrocytes.
  • Statistical Analysis: Standard statistical methods, including t-tests and ANOVA, were used to determine the significance of the observed differences.

Datasets

Not discussed in the paper. The study utilized established animal models and cell culture systems.

Key Insights and Ideas

  • Diabetes Impairs Synapses: The study found that diabetic brains exhibit reduced synaptophysin density, indicating a loss of synaptic connections, and increased C3 deposition at these synapses. This suggests a direct link between C3 and synaptic damage in diabetes.
  • Astrocytes are Key Players: C3 upregulation in diabetic conditions was specifically localized to astrocytes, both in vivo and in vitro. This highlights astrocytes as a critical cellular source of C3 in diabetic neuropathology.
  • RAGE is the Gatekeeper: The RAGE receptor plays a crucial role in mediating high glucose-induced C3 upregulation. Inhibiting RAGE significantly reduced C3 levels, suggesting it's an upstream regulator.
  • A Signaling Cascade: The study unraveled a specific signaling pathway: high glucose activates RAGE, which in turn activates p38MAPK and NF-κB. This cascade ultimately leads to increased C3 synthesis and secretion by astrocytes.
  • Therapeutic Potential: The findings point to the RAGE-p38MAPK-NF-κB pathway as a potential therapeutic target for mitigating diabetic cognitive decline by reducing C3-mediated synaptic damage.

Key Results

  • Elevated C3 in Diabetic Brains: Western blot analysis showed a significant increase in C3 protein levels in the hippocampus of STZ-induced diabetic mice compared to control mice.
  • Synaptic Loss in Diabetes: Immunofluorescence revealed decreased synaptophysin density and increased C3 co-localization with synaptophysin in diabetic brains, suggesting C3 is associated with synaptic protein loss.
  • RAGE, p38MAPK, and NF-κB Activation: In diabetic mice and high glucose-treated astrocytes, RAGE expression and phosphorylation of p38MAPK and NF-κB were significantly increased.
  • Inhibitor Efficacy: Pre-treatment with RAGE, p38MAPK, and NF-κB inhibitors effectively attenuated the high glucose-induced upregulation of C3 at the gene, protein, and secretion levels, both in vivo and in vitro.
  • C3 Upregulation by High Glucose: In primary astrocytes, high glucose concentrations (15 mM and 30 mM) dose-dependently increased C3 protein expression and secretion.
  • RAGE Inhibition Reverses Effects: Treatment with the RAGE inhibitor FPS-ZM1 reversed the high glucose-induced increases in C3, RAGE expression, and p38MAPK/NF-κB phosphorylation.

Limitations and Future Work

  • Causality of Synaptic Loss: While the study demonstrates a strong association between increased C3 and decreased synaptophysin density, it acknowledges that the direct causal role of C3 activation in causing synaptic loss requires further investigation.
  • Mechanism of C3 Action: The precise molecular mechanisms by which C3 mediates synaptic degeneration are not fully elucidated and warrant further research.
  • Translational Relevance: While the study provides insights into a potential therapeutic target, further research is needed to translate these findings into clinical applications for diabetic cognitive impairment.

The authors suggest that targeting the RAGE-p38MAPK-NF-κB signaling pathway could be a promising strategy for preventing or treating diabetes-associated neurodegenerative pathology.

Summary updated

Abstract

Diabetes is considered as a risk for cognitive decline, which is characterized by neurodegenerative alteration and innate immunity activation. Recently, complement 3 (C3), the critical central component of complement system, has been reported to play a key role in neurodegenerative alterations under pathological condition. Receptor for advanced glycation end products (RAGE) activation is confirmed to mediate several inflammatory cytokines production. However, whether C3 activation participates in the diabetic neuropathology and whether this process is regulated by RAGE activation remains unknown. The present study aimed to investigate the role of C3 in streptozotocin-induced diabetic mice and high glucose-induced primary astrocytes and the underlying modulatory mechanisms. The decreased synaptophysin density and increased C3 deposition at synapses were observed in the diabetic brain compared to the control brain. Furthermore, the elevated C3 was co-localized with GFAP-positive astrocytes in the diabetic brain slice in vivo and high glucose-induced astrocytes culture in vitro. Diabetes/high glucose-induced up-regulation of C3 expression at gene, protein and secretion levels, which were attenuated by pre-treatment with RAGE, p38MAPK and NF-κB inhibitors separately. These results demonstrate that high glucose induces C3 up-regulation via RAGE- p38MAPK-NF-κB signalling in vivo and in vitro, which might be associated with synaptic protein loss.
BibTeX
@article{zhao2018high,
  author = {Yuxing Zhao and Cheng Luo and Jinliang Chen and Yue Sun and Die Pu and Ankang Lv and Shiyu Zhu and Jing Wu and Meili Wang and Jing Zhou and Zhiyin Liao and Kexiang Zhao and Qian Xiao},
  title = {{High glucose‐induced complement component 3 up‐regulation via <scp>RAGE</scp>‐p38<scp>MAPK</scp>‐<scp>NF</scp>‐κB signalling in astrocytes: In vivo and in vitro studies}},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2018},
  doi = {10.1111/jcmm.13884},
}
Figure